The Shocking Predictions for Pliant Therapeutics Inc (PLRX) Stock You Can’t Ignore
Morgan Stanley has recently raised BILL Holdings Inc (BILL) stock rating, as announced on January 16, 2025, according to Finviz. Earlier, on January 10, 2025, Goldman had raised the stock from a Neutral to Buy, setting a price target of $104. KeyBanc Capital Markets also raised Overweight rating with a price target of $115. Additionally, […]
Morgan Stanley Just Upgraded BILL Holdings Inc (BILL) Stock—What Does This Mean for Investors?
Morgan Stanley has recently raised BILL Holdings Inc (BILL) stock rating, as announced on January 16, 2025, according to Finviz. Earlier, on January 10, 2025, Goldman had raised the stock from a Neutral to Buy, setting a price target of $104. KeyBanc Capital Markets also raised Overweight rating with a price target of $115. Additionally, […]
Uncover the Reason: Why BILL Holdings Inc (BILL) Stock Is Trading 123.03% Above Its 52-Week Low?
Morgan Stanley has recently raised BILL Holdings Inc (BILL) stock rating, as announced on January 16, 2025, according to Finviz. Earlier, on January 10, 2025, Goldman had raised the stock from a Neutral to Buy, setting a price target of $104. KeyBanc Capital Markets also raised Overweight rating with a price target of $115. Additionally, […]
BILL Holdings Inc (BILL) Stock: Beyond the Surface of Its Performance?
Morgan Stanley has recently raised BILL Holdings Inc (BILL) stock rating, as announced on January 16, 2025, according to Finviz. Earlier, on January 10, 2025, Goldman had raised the stock from a Neutral to Buy, setting a price target of $104. KeyBanc Capital Markets also raised Overweight rating with a price target of $115. Additionally, […]
Why Did BILL Holdings Inc (BILL) Stock Surge 6.39% Last Week?
Morgan Stanley has recently raised BILL Holdings Inc (BILL) stock rating, as announced on January 16, 2025, according to Finviz. Earlier, on January 10, 2025, Goldman had raised the stock from a Neutral to Buy, setting a price target of $104. KeyBanc Capital Markets also raised Overweight rating with a price target of $115. Additionally, […]
BILL Holdings Inc (BILL) Stock: A Deeper Look at Its True Potential
Morgan Stanley has recently raised BILL Holdings Inc (BILL) stock rating, as announced on January 16, 2025, according to Finviz. Earlier, on January 10, 2025, Goldman had raised the stock from a Neutral to Buy, setting a price target of $104. KeyBanc Capital Markets also raised Overweight rating with a price target of $115. Additionally, […]
BILL Holdings Inc’s Stock Drama: Could This Be a Game-Changer for BILL Investors?
Morgan Stanley has recently raised BILL Holdings Inc (BILL) stock rating, as announced on January 16, 2025, according to Finviz. Earlier, on January 10, 2025, Goldman had raised the stock from a Neutral to Buy, setting a price target of $104. KeyBanc Capital Markets also raised Overweight rating with a price target of $115. Additionally, […]
BILL Holdings Inc (BILL) Surge: Analyzing Today’s Price Increase
Goldman has recently raised BILL Holdings Inc (BILL) stock to Buy rating, as announced on January 10, 2025, according to Finviz. Earlier, on December 18, 2024, KeyBanc Capital Markets had raised the stock from a Sector Weight to Overweight, setting a price target of $115. Exane BNP Paribas also raised Outperform rating with a price […]
BILL Holdings Inc (BILL) Stock Price Reaches $83.2: What Factors Are Influencing This Level?
Goldman has recently raised BILL Holdings Inc (BILL) stock to Buy rating, as announced on January 10, 2025, according to Finviz. Earlier, on December 18, 2024, KeyBanc Capital Markets had raised the stock from a Sector Weight to Overweight, setting a price target of $115. Exane BNP Paribas also raised Outperform rating with a price […]
BILL Holdings Inc (BILL) Stock: Beyond the Surface of Its Performance?
KeyBanc Capital Markets has recently raised BILL Holdings Inc (BILL) stock to Overweight rating, as announced on December 18, 2024, according to Finviz. Earlier, on September 12, 2024, Exane BNP Paribas had raised the stock from a Neutral to Outperform, setting a price target of $90. BMO Capital Markets also reiterated Market Perform rating with […]
